Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

Phase 1/2 Completed 70 enrolled University of Wisconsin, Madison National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab

RandomizedCrossoverTriple-blindScreening

Summary

Double-blind, placebo-controlled, cross-over design study examining the effects of a norepinephrine alpha1 receptor antagonist (prazosin) on stress reactivity in a laboratory stressor task.

Timeline

Start: 2016-11-01
Primary completion: 2018-03-12
Completion: 2018-03-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prazosin	Unknown	2 mg	Oral

Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

Summary

Timeline

Drugs

Indications